From the Podium to Practice: Translating Emerging ATTR-CM Evidence Across Underserved and Underrecognized Populations

Overview

Learning Objectives

CME/ Information

Faculty and Disclosures

Instructions

From the Podium to Practice: Translating Emerging ATTR-CM Evidence Across Underserved and Underrecognized Populations is a four-part, mobile-accessible CME series designed to help clinicians translate emerging congress data into evidence-based care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Released approximately 45–60 days following four major cardiovascular congresses, each module focuses on critical gaps in recognition, diagnosis, and treatment across underrecognized patient populations, including women, African American patients with the p.Val142Ile variant, and patients presenting with atrial fibrillation or conduction system disease.

Through expert faculty commentary, interactive case-based learning, infographic-driven evidence summaries, embedded polling, and AI-generated patient video cases, learners will apply emerging clinical evidence to real-world diagnostic and treatment decisions. All four modules are housed within this learning experience and are designed for busy healthcare professionals seeking practical, immediately applicable education in ATTR-CM care.

Upon completion of this activity, the participant should be able to:

Identify female-specific ATTR-CM phenotypic features.
Apply adjusted diagnostic criteria in women presenting with HFpEF and ventricular wall thickening.
Select ATTR-CM therapy in women using emerging sex-stratified evidence, individualized to disease stage and functional status.
Apply structured diagnostic and genetic screening protocols to African American patients with HFpEF, wall thickening, or unexplained LVH, distinguishing V142I ATTR-CM from hypertensive cardiomyopathy.
Optimize treatment among available ATTR-CM therapies for p.Val142Ile patients based on disease stage, comorbidities, and cross-class comparative evidence; initiate cascade genetic screening.
Implement a structured ATTR-CM screening protocol for patients presenting to electrophysiologists with AF, AV block, bundle branch block, or unexplained conduction system disease.
Apply emerging arrhythmia-specific trial evidence to modify procedural planning, anticoagulation decisions, and TTR-directed therapy sequencing in patients with confirmed ATTR-CM and concomitant AF or conduction system disease.
Synthesize 2026 congress evidence across TTR stabilizer and silencer classes to identify practice-changing findings, recognize remaining guideline gaps

*Name of Planner or Manager*	*Reported Financial Relationship*
Conor Hughes	Nothing to disclose
Andrea Funk	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Deborah Sharkey	Nothing to disclose
Matthew Stern	Nothing to disclose
Alyssa Rossi	Nothing to disclose
Monique Walters	Nothing to disclose
Melissa Wiles	Nothing to disclose

Amit Goyal, MD, MAS (Chair)

Consulting Fee (e.g. Advisory Board) Shockwave Medical

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Stay Informed

To receive updates as soon as the new dates are confirmed, please share your email.

We appreciate your ongoing interest and look forward to keeping you informed with the latest details!

I would like to receive news and new program information

Thank you!

Overview

Learning Objectives

CME/ Information

Faculty and Disclosures

Instructions

AI Statement

Upon completion of this activity, the participant should be able to:

Identify the full NT1 symptom pentad and the systemic clinical burden of orexin deficiency.
Apply the cataplexy interrogation question at the CPAP non-response encounter.
Differentiate NT1 from NT2, idiopathic hypersomnia, and common misdiagnoses using the defining diagnostic criterion of cataplexy or CSF hypocretin-1 <110 pg/mL.
Distinguish NT1 from medication-induced and primary psychiatric EDS using ICSD-3 criteria when psychiatric comorbidity complicates evaluation of excessive daytime sleepiness.
Apply evidence-based PSG/MSLT diagnostic protocols, including medication washout requirements, SOREMP interpretation, and CSF hypocretin-1 <110 pg/mL as a standalone NT1 diagnostic criterion per ICSD-3.
Integrate SDoH-informed screening, navigator referral pathways, and telehealth-compatible approaches to reduce diagnostic delay in NT1 across diverse patient populations.
Individualize NT1 treatment selection using an SDM framework informed by the limitations of current pharmacotherapy and the mechanism of emerging OX2R-directed therapies.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium CE do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Professor of Psychiatry and Behavioral Sciences (Sleep

Medicine)

Chief of the Stanford Division of Sleep Medicine

Medical Director of the Stanford Sleep Medicine Center

Associate Chair and Professor in the Stanford Department of

Psychiatry and Behavioral Sciences at the Stanford

University Medical Center,

Director of the Stanford Human Sleep Research Laboratory

Disclosures

Consulting Fee (e.g., Advisory Board): Avadel Pharmaceuticals, SoundHealth Inc.. Alkermes, Lilly, Lundbeck, Apnimed, Eisai

Contracted Research (Principal Investigators must provide information, even if received by the institution): Samsung

Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Vivos Therapeutics

Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Asleep, SoundHealth Inc.

Narcolepsy Type 1 (NT1) remains substantially underrecognized, resulting in significant diagnostic delays and missed opportunities for timely treatment. This educational activity combines expert faculty presentations, a patient perspective, and an interactive AI-powered patient simulation to strengthen clinicians' ability to recognize NT1, apply evidence-based diagnostic strategies, address barriers to care, and integrate emerging therapies into patient-centered management. Through realistic clinical scenarios and practical discussion, participants will gain strategies to improve diagnostic accuracy and optimize outcomes for patients with NT1.

The simulated patient responds only within a case written and approved by the activity faculty, Clete A. Kushida, MD, PhD, and Atul Malhotra, MD. Clinical content is limited to a closed set of sources: current clinical guidelines and the references cited in the activity slides (see the reference list), current as of October 12, 2026.

The AI does not search the internet. It does not give you diagnostic or treatment recommendations. Before release, the faculty and the IridiumCE and Global Education Group planners, tested the simulation for accuracy, completeness, balance and freedom from commercial bias on October 12, 2026.

Platform: Patient dialogue is generated using OpenAI's GPT-4.1 model (gpt-4.1-2025-04-14). The patient's video avatar is powered by HeyGen.

Independence. Global, as the accredited provider, is responsible for all content in this activity, including what the AI generates.

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. Takeda had no role in writing the case, configuring the AI, or deciding how it is scored. Scores reflect your clinical reasoning and communication, not which treatment is chosen. No product advertising is provided within activity.

Limitations. AI can make mistakes. Responses may occasionally be incomplete, worded unexpectedly, or wrong. Known limitations for this case, e.g. the patient cannot respond to physical-exam maneuvers outside the menu. This simulation is for educational purposes only and is not clinical guidance. The learners remain responsible for their own clinical decisions. If a response seems inaccurate or inappropriate, select Flag.

A clinical reviewer will review it.

Data. All conversation and scores are recorded so we can give personalized feedback, award credit, and evaluate and improve the activity.

Transcripts are stored apart from your name and analyzed in de-identified form. Iridium Continuing Education holds the transcripts in secure, access-controlled systems.

Learner data is never sold, never shared with commercial supporters except as aggregate de-identified results, and never used to train outside AI models.

Your voice is used only to transcribe your words. Your voice is never copied, cloned or used to create a synthetic voice. Please do not enter information about real patients.

Compliance. This use of AI follows the Accreditation Council for Continuing Medical Education (ACCME) Guidance on the Responsible Use of Artificial Intelligence in Accredited Continuing Education (January 30, 2026) and its Urgent Alert on the Use of AI in Accredited CE (April 14, 2026). It also meets the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Questions? Contact info@iridiumce.com.